-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RLKTPtIb2PBcR4KAzqp28CnhymUFKwR0wXHDpPSjJ95jF3ANiSS6iGO8gs/7xoh9 f4kFZjUJ3t3AbdCEuR2OXg== 0001254316-05-000143.txt : 20051114 0001254316-05-000143.hdr.sgml : 20051111 20051114122442 ACCESSION NUMBER: 0001254316-05-000143 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051109 FILED AS OF DATE: 20051114 DATE AS OF CHANGE: 20051114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EBERSMAN DAVID A CENTRAL INDEX KEY: 0001214123 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09813 FILM NUMBER: 051198509 MAIL ADDRESS: STREET 1: C/O GENENTECH INC STREET 2: 1 DNA WAY MS 49 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-4990 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENENTECH INC CENTRAL INDEX KEY: 0000318771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 942347624 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 DNA WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-225-1000 MAIL ADDRESS: STREET 1: 1 DNA WAY STREET 2: . CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2005-11-09 0 0000318771 GENENTECH INC DNA 0001214123 EBERSMAN DAVID A 1 DNA WAY SO SAN FRANCISCO CA 94080 0 1 0 0 SR VP & CFO Common Stock 2005-11-09 4 M 0 100 40.99 A 7533 D Common Stock 2005-11-09 4 S 0 100 93.39 D 7433 D Common Stock 2005-11-09 4 M 0 49900 40.99 A 57333 D Common Stock 2005-11-09 4 S 0 49900 92.85 D 7433 D Non-Qualified Stock Option (right to buy) 40.99 2005-11-09 4 M 0 100 0 D 2000-09-20 2010-09-20 Common Stock 100 99900 D Non-Qualified Stock Option (right to buy) 40.99 2005-11-09 4 M 0 49900 0 D 2000-09-20 2010-09-20 Common Stock 49900 50000 D This stock option vests over four years, with the first 25% of the shares vesting one year from the grant date and 75% of the shares vesting in equal monthly increments over the following three years. This option may be immediately exercisable with the consent of Genentech. David A. Ebersman 2005-11-10 -----END PRIVACY-ENHANCED MESSAGE-----